You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm's product sales were down almost 14 percent year over year in Q4.
Natera saw total Q4 2016 revenues decline to $49.3 million, despite an increase in testing volumes.
A decline in collaboration revenues more than offset revenue gains for the company's Idylla platform and test cartridges.
The firm touted recent Blues coverage decisions for the Afirma thyroid cancer test, and final Medicare coverage policies for the Percepta lung cancer test.
The firm said that during the quarter, service revenues from its BioReference Laboratories business increased by $12.8 million compared to the year-ago period.
The company attributed the decline to lower revenues from its collaboration with Quest Diagnostics.
CEO Hany Massarany said that 2017 will be a pivotal year for the company as it expects to launch the ePlex sample-to-answer system in the US.
The firm believes that its definitive monomicrobial test, which usually eliminates the need for additional validation testing, may give it an edge over competitors.
The firm reported preliminary revenues of $246,000 for 2016, and said that after receiving FDA clearance, it expects a lift in sales of its ID/AST blood-based infection test.
The firm's full-year loss per share was unchanged from the prior year, but its Q4 loss dropped about 9 percent to $3.1 million compared to the year-ago quarter.